Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Arcxis Biotechnologies, a privately-held biomedical device company, has completed the first close of its series B round. Claremont Creek Ventures, who led the round, was joined by Kaiser Permanente Ventures and Alafi Capital.
Subscribe to our email newsletter
These funds will enable Arcxis to accelerate development, testing, and commercialization of their innovative nucleic acid sample preparation platform and their next generation sample to answer clinical molecular diagnostic platform.
John Steuart, managing director of Arcxis Biotechnologies, said: “Claremont Creek Ventures is excited about the ongoing investment in Arcxis which will help the company bring this important new technology to clinical molecular laboratories around the world.”